Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in Health) to develop its malaria
vaccine. GSK’s vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials—the best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas “at a very reasonable price”.
To continue reading, today with our introductory offers
Advertisement
More from 51¶¯Âþ
Explore the latest news, articles and features
Popular articles
Trending 51¶¯Âþ articles
1
The Selfish Gene at 50: Why Dawkins’s evolution classic still holds up
2
How I used psychology to come back from the worst year of my life
3
Photos reveal unexpected details from the world's first atomic test
4
Mathematicians stunned by AI's biggest breakthrough in mathematics yet
5
Putting CO2 into rocks and getting hydrogen out is climate double win
6
Can we harness quantum effects to create a new kind of healthcare?
7
We may finally know why dinosaurs like T. rex evolved tiny arms
8
Epic dreaming is leaving people exhausted and distressed
9
Colossal claims an artificial eggshell will help it bring back the moa
10
The ‘doomsday’ glacier’s giant ice shelf is about to break away
